Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER

Trial Profile

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pramipexole/rasagiline (Primary) ; Pramipexole; Pramipexole; Rasagiline
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharma Two B

Most Recent Events

  • 22 Jul 2024 According to a Pharma Two B media release, the company is planning to file an NDA for P2B001 in first half of 2026.
  • 18 Apr 2024 Integrated analysis Results(phase 2 (NCT01968460) and phase 3 (NCT03329508), n=199) evaluating safety and tolerability profile, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 09 Nov 2023 Results presented in a Pharma Two B Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top